Clearside Biomedical, Inc. Announces Fourth Patent Allowance in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices

Print 04 September 2014

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., announces the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 13/447,246 as U.S. Patent No. 8,808,225 in a patent titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the fourth patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices.

U.S. Patent No. 8,808,225 provides exclusivity for the administration of any drug to an eye of a patient by inserting a hollow microneedle into the patient’s eye and infusing the drug into the suprachoroidal space of the patient’s eye. The patent, exclusively licensed to Clearside, is the fourth generated from Clearside’s alliance with the Georgia Tech Research Corporation and Emory University.

In April 2011, June 2012 and January 2014, the USPTO issued method and device patents covering the Company's drug delivery methods and devices for carrying out the methods.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space with Clearside’s proprietary microinjector. Visit www.clearsidebio.com for more information.

 

Return